Sharon Benzeno - Mar 4, 2022 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Role: Chief Business Development Off
Signature: /s/ Sharon Benzeno by Eric Billings, attorney-in-fact
Stock symbol: ADPT
Transactions as of: Mar 4, 2022
Transactions value $: -$32,067
Form type: 4
Date filed: 3/8/2022, 08:01 PM
Next filing: Mar 8, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ADPT	Common Stock	Award	$0	+82.4K	+359.8%	$0.00	105K	Mar 4, 2022	Direct
transaction	ADPT	Common Stock	Sale	-$32.1K	-2.67K	-2.54%	$12.01	103K	Mar 7, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADPT	Stock Option (Right to Buy)	Award	$0	+206K		$0.00	206K	Mar 4, 2022	Common Stock	206K	$12.14	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F2	The options vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

Content

This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

The options vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.